EMEA-000574-PIP02-12-M03
Key facts
Invented name |
Blincyto
|
Active substance |
blinatumomab
|
Therapeutic area |
Oncology
|
Decision number |
P/0143/2020
|
PIP number |
EMEA-000574-PIP02-12-M03
|
Pharmaceutical form(s) |
Powder for solution for infusion
|
Condition(s) / indication(s) |
Treatment of acute lymphoblastic leukaemia
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Amgen Europe B.V.
E-mail: medinfointernational@amgen.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|